Anda di halaman 1dari 3

March 21, 2012

ATTENTION Investors and Finance Professionals:


If you are reading this you should sign up for ValuEngine's award-winning stock valuation and forecast service at the low price of $19.95/month! NO OBLIGATION, 14 Day FREE TRIAL!

CLICK HERE

Another Big Pharma Gainer


Amarin Corporation (AMRN,$AMRN) Up 34% in Five Days for the ValuEngine Forecast 16 Newsletter Amarin Corporation plc (AMRN) is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. Amarin was the Medical Sector primary long pick for our VE Diversified Growth Strategy and our VE Forecast 16 Market Neutral Strategy Newsletter this month. So far, it has provided a return in excess of 34%. Amarin jumped more than 12% yesterday on news that the US Patent Office has approved a patent for AMR-101, a treatment for high glycerides. ValuEngine has issued a STRONG BUY recommendation for AMARIN CORP PLC on Mar. 21, 2012. Based on the information we have gathered and our resulting research, we feel that AMARIN CORP PLC has the probability to OUTPERFORM average market performance for the next year. The company exhibits ATTRACTIVE market valuation, P/E ratio and momentum.

Based on available data as of Mar. 21, 2012, we believe that AMRN should be trading at $40.23. This makes AMRN 70.32% undervalued. Fair Value indicates what we believe the stock should be trading at today if the stock market were perfectly efficient and everything traded at its true worth. For AMRN, we base this on actual earnings per share (EPS) for the previous four quarters of $2.25, forecasted EPS for the next four quarters of -$0.11, and correlations to the 30- year Treasury bond yield of 3.46%.
ValuEngine Forecast Target Price*
1-Month 3-Month 6-Month 1-Year 2-Year 3-Year 12.37 12.97 13.78 15.49 15.77 15.64

Expected Return
3.59% 8.66% 15.41% 29.77% 32.12% 30.95%

Valuation & Rankings


Valuation 1-M Forecast Return 12-M Return Sharpe Ratio 5-Y Avg Annual Return Volatility Expected EPS Growth Market Cap (billions) Trailing P/E Ratio Forward P/E Ratio PEG Ratio Price/Sales Market/Book Beta Alpha 70.32% undervalued 3.59% 66.30% -0.13 -13.11% 97.66% -104.81% 1.62 5.3 n/a n/a n/a n/a 1.27 0.54 Valuation Rank 1-M Forecast Return Rank Momentum Rank Sharpe Ratio Rank 5-Y Avg Annual Rtn Rank Volatility Rank EPS Growth Rank Size Rank Trailing P/E Rank Forward P/E Ratio Rank PEG Ratio Rank Price/Sales Rank Market/Book Rank Beta Rank Alpha Rank 98 100 97 50 38 13 2 77 98 n/a n/a n/a n/a 41 96

Click HERE to Download a FREE Sample of Our Best Performing Newsletter

Market Overview
Summary of VE Stock Universe
Stocks Undervalued Stocks Overvalued Stocks Undervalued by 20% Stocks Overvalued by 20% 48.39% 51.61% 20.20% 19.19%

Sector
Aerospace Auto-Tires-Trucks Basic Materials Business Services Computer and Technology Construction Consumer Discretionary Consumer Staples Finance Industrial Products Medical Multi-Sector Conglomerates Oils-Energy Retail-Wholesale Transportation Utilities

Change
-1.56% -1.35% -0.94% -0.85% -0.49% -1.00% -0.39% -0.44% -0.47% -1.16% -0.91% -0.89% -0.94% -0.10% -1.00% -0.52%

MTD
-1.47% -0.06% -3.59% 0.82% 1.36% 3.89% 3.49% 0.55% 3.24% 0.53% 1.46% 0.39% -2.31% 2.53% 0.80% 0.20%

YTD
5.50% 18.72% 8.41% 9.76% 15.38% 20.33% 16.22% 8.55% 14.54% 12.69% 12.51% 13.82% 7.30% 14.54% 13.74% 3.69%

Valuation
4.12% overvalued 4.09% overvalued 3.16% overvalued 2.29% undervalued 25.65% overvalued 4.64% overvalued 5.26% overvalued 9.30% overvalued 22.92% overvalued 9.52% overvalued 13.34% overvalued 9.56% overvalued 2.69% overvalued 17.49% overvalued 10.10% overvalued 8.52% overvalued

Last 12P/E MReturn Ratio


-6.22% -5.40% -22.70% 2.95% -6.63% -8.35% 2.97% -3.19% 0.44% -7.63% -5.49% 2.00% -19.26% 12.66% -13.36% 1.30% 15.85 30.19 26.38 32.63 46.01 37.55 30.68 28.57 23.3 25.65 36.41 19.58 38.67 22.01 25.51 30.99